Modulation of p53 expression by human recombinant interferon-α2a correlates with abrogation of cisplatin resistance in a human melanoma cell line

Cancer Research

Volumn 56, Issue 11, 1996, Pages 2522-2526

  Davol, Pamela A ^a   Goulette, Frederick A ^a   Frackelton Jr , A Raymond ^a   Darnowski, James W ^a,b  

^a BROWN UNIVERSITY   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUOROURACIL; MITOMYCIN C; PROPIDIUM IODIDE; PROTEIN P53; RECOMBINANT ALPHA2A INTERFERON; TETRAPLATIN;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE PHASE; CELL SURVIVAL; COLONY FORMATION; CONTROLLED STUDY; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG RESISTANCE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MELANOMA CELL; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

CELL SURVIVAL; CISPLATIN; DNA DAMAGE; DRUG RESISTANCE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; INTERFERON ALFA-2A; MELANOMA; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029982179     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Hartwell, L. H., and Weinert, T A. Checkpoints: controls that ensure order of cell cycle events. Science, 246: 629-634, 1989.
2. 1 arrest and apoptosis. Cancer Res., 54. 1169-1174, 1994.
3. Kastan, M. B , Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
4. Nelson, W G., and Kastan, M. B. DNA strand breaks: the DNA template alterations that trigger p53-dependem DNA damage response pathways. Mol. Cell. Biol., 14: 1815-1823, 1994.
5. El-Deiry, W. S., Tokino, T., Velculescu, V. E , Levy, D B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinsler, K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
6. Ewen, M. E , Sluss, H. K , Sherr, E. J., Matsushime, H , Kato, J -Y., and Livingston, D.M Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell, 73 487-497, 1993
7. Nevins, J. R E2F, a link between the Rb tumor suppressor protein and viral oncoproteins Science, 258: 424-429, 1992.
8. Mercer, W. E , Shields, M. T., Amin, M., Suave, G. J , Apella, E., and Ulrich, S. J. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc. Natl. Acad. Sci. USA, 87: 6166-6170, 1992
9. Sklarin, N. T., Chahinian, A. P., and Feuer, E. J. Augmentation of activity of cis-diamminedichloroplatinum (II) and mitomycin C by interferon in human malignant mesothelioma xenografts in nude mice. Cancer Res., 48: 64-67, 1988.
10. Legha, S. S Current therapy for melanoma Semin. Oncol., 16: 34-44, 1989.
11. Schuchter, L. M., Wohlganger, J., Fishman, E K., MacDermott, M. L , and McGuire, W P Sequential chemotherapy and immunotherapy for the treatment of metastatic melanoma. J. Immunother., 12: 272-276, 1992.
12. Margolin, K. A., Doroshaw, J. H., Akman, S. A., Leong, L. A., Morgan, R. J., Somlo, G., Raschko, J., Pereira, C., Yonemoto, L., and Ahn, C Phase II trial of cisplarin and α-interferon in advanced malignant melanoma J. Clin Oncol., 10: 1574-1578, 1992.
13. Teicher, B. A , and Frei III, E. Development of alkylating agent-resistant human tumor cell lines. Cancer Chemother. Pharmacol., 21, 292-298, 1988.
14. Teicher, B A., Holden, S. A., Herman, T S , Alvarez-Sotomayor, E., Khandekar, V., Rosbe, K. W. Brann, T. W., Korbut, T. T., and Frei, E , III. Characteristics of five human tumor cell lines and sublines resistant to cis-diamminedichloroplatinum (II). Int. J. Cancer. 47: 252-260, 1991.
15. McKendrick, L, and Meek, D. W. A novel system to investigate the phosphorylation of the p53 tumor suppressor protein by the protein kinase CK2. Cell. Mol. Biol. Res., 40, 529-537, 1994.
16. Tishler, R. B., Calderwood, S. K., Coleman, C. N., and B. D. Price. Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents. Cancer Res , 53: 2212-2216, 1993.
17. Vadhan-Raj, S., Broxmeyer, H. E , and Hittelman, W. N. Abrogating chemotherapy-induced myeolsuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level. J. Clin. Oncol., 10: 1266-1277, 1992.
18. Yan, C , and Tamm, I Identification of a new interferon-α/β inducible DNA-binding protein that interacts with the regulatory element of 2′5′-oligoadenylate synthetase ME-12 gene. J. Interfer. Res., 12: 425-430, 1992.
19. Friedman, R L., Manly, S. P , McMahon, M., Kerr, I M., and Stark, G. R. Transcriptional and post-transcriptional regulation of interferon-induced gene expression in human cells. Cell, 38: 745-755, 1984.
20. Clark, J. W., and Longo, D L Interferons in cancer therapy. Cancer Updates, 1: 1-15, 1987.